SynthesisPloS one2022

Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.

Patrick Daniele et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.